SSI Diagnostica (Adelis) Acquires TECHLAB, Inc. from Pharos Capital

SSI Diagnostica (Adelis portfolio) Acquires CTK Biotech

August 26, 2020

Medical Devices

Adelis Equity Partners portfolio company SSI Diagnostica has acquired US-based CTK Biotech to create a global rapid diagnostics leader focused on respiratory and tropical disease tests. The deal combines SSI Diagnostica's Nordic IVD capabilities and distribution with CTK's product development and manufacturing (headquartered in San Diego with a manufacturing plant in Beijing), and triggers a CEO change and several board appointments.

Quest Diagnostics Acquires Labtech Diagnostics

December 14, 2021

Healthcare Services

Quest Diagnostics has acquired substantially all assets of Labtech Diagnostics, an independent clinical diagnostic laboratory based in Anderson, South Carolina. The acquisition brings Labtech into Quest’s national laboratory network — Quest’s first full-service laboratory in South Carolina — and expands Quest’s diagnostic capabilities and presence across the Southeast.

Adelis Equity Partners Becomes Majority Owner of Nordic BioSite Group

May 28, 2021

Healthcare Services

Adelis Equity Partners has acquired a majority stake in Nordic BioSite Group to accelerate the group's growth and pan‑European expansion of its life‑science research and diagnostics distribution platform. Tellacq Partners, together with the founders and management team, had built the group (including Nordic Biosite AB, Sanbio BV and Biomol GmbH); the parties did not disclose the purchase price.

SSI Diagnostica Group Acquires Gulf Coast Scientific

April 28, 2025

Medical Devices

SSI Diagnostica Group (Denmark) has acquired Gulf Coast Scientific, a Florida-based in‑vitro diagnostics company specializing in Urea Breath Testing for Helicobacter pylori. The deal expands SSI Diagnostica Group's gastrointestinal diagnostic portfolio and strengthens its footprint in the US clinical diagnostics market.

Charles River Laboratories Acquires SAMDI Tech

January 30, 2023

Biotechnology

Charles River Laboratories acquired the remaining 80% stake in SAMDI Tech for $50 million in cash, completing a transaction that follows a partnership begun in 2018. The acquisition integrates SAMDI Tech's proprietary mass spectrometry high-throughput screening technology into Charles River's Discovery and Safety Assessment segment to strengthen drug discovery capabilities and accelerate hit identification for pharmaceutical and biotech clients.

Adelis Equity Partners Acquires Majority Stake in Axentia Technologies

July 6, 2020

Transportation

Adelis Equity Partners has acquired slightly more than 50% of Axentia Technologies, becoming the company's majority owner while founders and management retain a significant stake. The investment will support Axentia's product development and international expansion of its low-power connected display systems and related software for the public transportation and rescue markets.